Copyright Reports & Markets. All rights reserved.

Global Omalizumab Biologic Injection Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Omalizumab Biologic Injection by Type
    • 1.3.1 Overview: Global Omalizumab Biologic Injection Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Omalizumab Biologic Injection Consumption Value Market Share by Type in 2025
    • 1.3.3 150 mg/mL
    • 1.3.4 75 mg/0.5 mL
  • 1.4 Classification of Omalizumab Biologic Injection by Age
    • 1.4.1 Overview: Global Omalizumab Biologic Injection Market Size by Age: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Omalizumab Biologic Injection Consumption Value Market Share by Age in 2025
    • 1.4.3 For Adults
    • 1.4.4 For Teenagers
    • 1.4.5 For Children
  • 1.5 Global Omalizumab Biologic Injection Market by Application
    • 1.5.1 Overview: Global Omalizumab Biologic Injection Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.5.2 Hospital
    • 1.5.3 Clinic
    • 1.5.4 Others
  • 1.6 Global Omalizumab Biologic Injection Market Size & Forecast
  • 1.7 Global Omalizumab Biologic Injection Market Size and Forecast by Region
    • 1.7.1 Global Omalizumab Biologic Injection Market Size by Region: 2021 VS 2025 VS 2032
    • 1.7.2 Global Omalizumab Biologic Injection Market Size by Region, (2021-2032)
    • 1.7.3 North America Omalizumab Biologic Injection Market Size and Prospect (2021-2032)
    • 1.7.4 Europe Omalizumab Biologic Injection Market Size and Prospect (2021-2032)
    • 1.7.5 Asia-Pacific Omalizumab Biologic Injection Market Size and Prospect (2021-2032)
    • 1.7.6 South America Omalizumab Biologic Injection Market Size and Prospect (2021-2032)
    • 1.7.7 Middle East & Africa Omalizumab Biologic Injection Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Roche
    • 2.1.1 Roche Details
    • 2.1.2 Roche Major Business
    • 2.1.3 Roche Omalizumab Biologic Injection Product and Solutions
    • 2.1.4 Roche Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Recent Developments and Future Plans
  • 2.2 Novartis
    • 2.2.1 Novartis Details
    • 2.2.2 Novartis Major Business
    • 2.2.3 Novartis Omalizumab Biologic Injection Product and Solutions
    • 2.2.4 Novartis Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Novartis Recent Developments and Future Plans
  • 2.3 Glenmark Pharmaceuticals
    • 2.3.1 Glenmark Pharmaceuticals Details
    • 2.3.2 Glenmark Pharmaceuticals Major Business
    • 2.3.3 Glenmark Pharmaceuticals Omalizumab Biologic Injection Product and Solutions
    • 2.3.4 Glenmark Pharmaceuticals Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Glenmark Pharmaceuticals Recent Developments and Future Plans
  • 2.4 Selexis
    • 2.4.1 Selexis Details
    • 2.4.2 Selexis Major Business
    • 2.4.3 Selexis Omalizumab Biologic Injection Product and Solutions
    • 2.4.4 Selexis Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Selexis Recent Developments and Future Plans
  • 2.5 Generium
    • 2.5.1 Generium Details
    • 2.5.2 Generium Major Business
    • 2.5.3 Generium Omalizumab Biologic Injection Product and Solutions
    • 2.5.4 Generium Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Generium Recent Developments and Future Plans
  • 2.6 CuraTeQ
    • 2.6.1 CuraTeQ Details
    • 2.6.2 CuraTeQ Major Business
    • 2.6.3 CuraTeQ Omalizumab Biologic Injection Product and Solutions
    • 2.6.4 CuraTeQ Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 CuraTeQ Recent Developments and Future Plans
  • 2.7 Celltrion Healthcare
    • 2.7.1 Celltrion Healthcare Details
    • 2.7.2 Celltrion Healthcare Major Business
    • 2.7.3 Celltrion Healthcare Omalizumab Biologic Injection Product and Solutions
    • 2.7.4 Celltrion Healthcare Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Celltrion Healthcare Recent Developments and Future Plans
  • 2.8 Alvotech
    • 2.8.1 Alvotech Details
    • 2.8.2 Alvotech Major Business
    • 2.8.3 Alvotech Omalizumab Biologic Injection Product and Solutions
    • 2.8.4 Alvotech Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Alvotech Recent Developments and Future Plans
  • 2.9 BiosanaPharma
    • 2.9.1 BiosanaPharma Details
    • 2.9.2 BiosanaPharma Major Business
    • 2.9.3 BiosanaPharma Omalizumab Biologic Injection Product and Solutions
    • 2.9.4 BiosanaPharma Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 BiosanaPharma Recent Developments and Future Plans
  • 2.10 Mabpharm
    • 2.10.1 Mabpharm Details
    • 2.10.2 Mabpharm Major Business
    • 2.10.3 Mabpharm Omalizumab Biologic Injection Product and Solutions
    • 2.10.4 Mabpharm Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Mabpharm Recent Developments and Future Plans
  • 2.11 CSPC Pharmaceutical Group
    • 2.11.1 CSPC Pharmaceutical Group Details
    • 2.11.2 CSPC Pharmaceutical Group Major Business
    • 2.11.3 CSPC Pharmaceutical Group Omalizumab Biologic Injection Product and Solutions
    • 2.11.4 CSPC Pharmaceutical Group Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 CSPC Pharmaceutical Group Recent Developments and Future Plans
  • 2.12 Biomabs
    • 2.12.1 Biomabs Details
    • 2.12.2 Biomabs Major Business
    • 2.12.3 Biomabs Omalizumab Biologic Injection Product and Solutions
    • 2.12.4 Biomabs Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Biomabs Recent Developments and Future Plans
  • 2.13 HisunPharm
    • 2.13.1 HisunPharm Details
    • 2.13.2 HisunPharm Major Business
    • 2.13.3 HisunPharm Omalizumab Biologic Injection Product and Solutions
    • 2.13.4 HisunPharm Omalizumab Biologic Injection Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 HisunPharm Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Omalizumab Biologic Injection Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Omalizumab Biologic Injection by Company Revenue
    • 3.2.2 Top 3 Omalizumab Biologic Injection Players Market Share in 2025
    • 3.2.3 Top 6 Omalizumab Biologic Injection Players Market Share in 2025
  • 3.3 Omalizumab Biologic Injection Market: Overall Company Footprint Analysis
    • 3.3.1 Omalizumab Biologic Injection Market: Region Footprint
    • 3.3.2 Omalizumab Biologic Injection Market: Company Product Type Footprint
    • 3.3.3 Omalizumab Biologic Injection Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Omalizumab Biologic Injection Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Omalizumab Biologic Injection Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Omalizumab Biologic Injection Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Omalizumab Biologic Injection Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Omalizumab Biologic Injection Consumption Value by Type (2021-2032)
  • 6.2 North America Omalizumab Biologic Injection Market Size by Application (2021-2032)
  • 6.3 North America Omalizumab Biologic Injection Market Size by Country
    • 6.3.1 North America Omalizumab Biologic Injection Consumption Value by Country (2021-2032)
    • 6.3.2 United States Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Omalizumab Biologic Injection Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Omalizumab Biologic Injection Consumption Value by Type (2021-2032)
  • 7.2 Europe Omalizumab Biologic Injection Consumption Value by Application (2021-2032)
  • 7.3 Europe Omalizumab Biologic Injection Market Size by Country
    • 7.3.1 Europe Omalizumab Biologic Injection Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 7.3.3 France Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Omalizumab Biologic Injection Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Omalizumab Biologic Injection Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Omalizumab Biologic Injection Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Omalizumab Biologic Injection Market Size by Region
    • 8.3.1 Asia-Pacific Omalizumab Biologic Injection Consumption Value by Region (2021-2032)
    • 8.3.2 China Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 8.3.5 India Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Omalizumab Biologic Injection Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Omalizumab Biologic Injection Consumption Value by Type (2021-2032)
  • 9.2 South America Omalizumab Biologic Injection Consumption Value by Application (2021-2032)
  • 9.3 South America Omalizumab Biologic Injection Market Size by Country
    • 9.3.1 South America Omalizumab Biologic Injection Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Omalizumab Biologic Injection Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Omalizumab Biologic Injection Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Omalizumab Biologic Injection Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Omalizumab Biologic Injection Market Size by Country
    • 10.3.1 Middle East & Africa Omalizumab Biologic Injection Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Omalizumab Biologic Injection Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Omalizumab Biologic Injection Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Omalizumab Biologic Injection Market Drivers
  • 11.2 Omalizumab Biologic Injection Market Restraints
  • 11.3 Omalizumab Biologic Injection Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Omalizumab Biologic Injection Industry Chain
  • 12.2 Omalizumab Biologic Injection Upstream Analysis
  • 12.3 Omalizumab Biologic Injection Midstream Analysis
  • 12.4 Omalizumab Biologic Injection Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Omalizumab Biologic Injection market size was valued at US$ 66.80 million in 2025 and is forecast to a readjusted size of US$ 129 million by 2032 with a CAGR of 8.5% during review period.
    Omalizumab Biologic Injection is a monoclonal antibody drug targeting immunoglobulin E (IgE), mainly used for the treatment of allergic asthma, chronic spontaneous urticaria, nasal polyps, and other IgE-mediated diseases. It works by binding to free IgE in the blood, thereby reducing allergic reactions and inflammation. Upstream of the industry chain mainly includes biotechnology raw materials, cell culture media, recombinant protein expression systems, bioreactor equipment, and contract development and manufacturing organizations (CDMOs). Midstream consists of biopharmaceutical companies producing original biologics and biosimilars, formulation manufacturers, fill-finish providers, and cold chain logistics companies. Downstream includes hospitals, specialty clinics, retail pharmacies, online pharmacies, and patients suffering from severe allergic or autoimmune-related conditions. With the growing prevalence of allergic diseases and the expansion of biologic therapies, the market demand for Omalizumab Injection continues to increase globally.
    This report is a detailed and comprehensive analysis for global Omalizumab Biologic Injection market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Omalizumab Biologic Injection market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Omalizumab Biologic Injection market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Omalizumab Biologic Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Omalizumab Biologic Injection market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Omalizumab Biologic Injection
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Omalizumab Biologic Injection market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech, BiosanaPharma, Mabpharm, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Omalizumab Biologic Injection market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    150 mg/mL
    75 mg/0.5 mL
    Market segment by Age
    For Adults
    For Teenagers
    For Children
    Market segment by Application
    Hospital
    Clinic
    Others
    Market segment by players, this report covers
    Roche
    Novartis
    Glenmark Pharmaceuticals
    Selexis
    Generium
    CuraTeQ
    Celltrion Healthcare
    Alvotech
    BiosanaPharma
    Mabpharm
    CSPC Pharmaceutical Group
    Biomabs
    HisunPharm
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Omalizumab Biologic Injection product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Omalizumab Biologic Injection, with revenue, gross margin, and global market share of Omalizumab Biologic Injection from 2021 to 2026.
    Chapter 3, the Omalizumab Biologic Injection competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Omalizumab Biologic Injection market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Omalizumab Biologic Injection.
    Chapter 13, to describe Omalizumab Biologic Injection research findings and conclusion.

    Buy now